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Abstract
The problem of drug shortages has been reported worldwide, gaining prominence in multi-
ple domains and several countries in recent years. The aim of the study was to analyze,
characterise and assess this problem in Belgium and France, while also adopting a wider
perspective from the European Union. A qualitative methodological approach was em-
ployed, including semi-structured interviews with the representatives of respective national
health authorities, pharmaceutical companies and wholesalers, as well as hospital and
community pharmacists. The research was conducted in early 2014. Four themes, which
were identified through the interviews, were addressed in the paper, i.e. a) defining drug
shortages, b) their dynamics and perception, c) their determinants, d) the role of the Europe-
an and national institutions in coping with the problem. Three groups of determinants of
drug shortages were identified throughout this study: manufacturing problems, distribution
and supply problems, and problems related to economic aspects. Currently, the Member
States of the European Union are striving to resolve the problem very much on their own, al-
though a far more focused and dedicated collaboration may well prove instrumental in cop-
ing with drug shortages throughout Europe more effectively. To the best of the authors’
knowledge, this is the first qualitative study to investigate the characteristics, key determi-
nants, and the problem drivers of drug shortages, focusing on this particular group of coun-
tries, while also adopting the European Union’s perspective.
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Introduction
Drug shortages have been reported for several years, although it is only recently that the reports
seem to be gaining prominence in several classes of medicines and in multiple countries [1–4].
The World Health Organization (WHO) described medicine shortages as a complex global
challenge, affecting more than 20 countries worldwide [5]. For the purpose of this study, drug
shortages were defined as a situation in which the current or projected demand of a medicine
at user level is inadequately met. Their origins are complex, diverse and differ among regions
and countries [6–8]. A non-exhaustive list of causes for drug shortages was provided recently
by Birgli’s research, including those stemming from both unpredictable and predictable rea-
sons [6]. According to this source, the first group of reasons comprises: natural disasters,
manufacturing problems, raw material shortages, non-compliance with regulatory standards,
packaging shortages, unexpected demand, epidemics, parallel distribution, competitive issues,
foreign exchange effects and sovereign issues (financial crisis, debt, default). The second group
of reasons comprises: product discontinuation, industry consolidation (mergers and acquisi-
tions), limited manufacturing capacity, just-in-time inventories, rationing/quotas, deliberate
shortages used to manipulate prices, market shifts, launches of new competitors, new formula-
tions, or patent expiry.
Regardless of the cause, drug shortages have an impact on all stakeholders in the supply
chain. When they occur, patients may not receive their medication, or an alternative treatment
will have to be found to substitute for the missing product. This can lead to inconvenience and
distress or clinical risks such as medication errors, adverse effects and disease progression. The
published empirical evidence is often based on the North American experience, including the
USA or Canada, where the effects of medicine shortages have been researched more extensively
than in Europe [9–17]. In order to find alternative treatments, pharmacy personnel will have to
spend extra time on alternative sourcing for medications [18]. A study carried out in 2011 by
Chemist & Druggist indicated that 95% of pharmacists in the UK spent between one and two
hours per week tracking out-of-stock medicines [19]. The estimated labour cost linked with
management of drug shortages was set at $216 million annually in the USA alone [20]. Fur-
thermore, the cost of purchasing alternative medicines adds to the financial burden of US hos-
pital pharmacies due to reimbursement restrictions [9,10]. It is estimated to cost the US
hospitals approximately $215 million annually [21].
The study aimed to analyse, characterise and assess the problem of drug shortages in Bel-
gium and France. A multidimensional character of this issue and the perspective of the Europe-
an Union (EU) were taken into account. The research tasks focused on investigating present
appreciation and interpretation of the drug shortages phenomenon, as well as its determinants
and problem drivers.
It is difficult to characterise and assess the problem of drug shortages by using quantita-
tive methods only, due to the following reasons. First of all, there is a scarcity of publicly
available data on drug shortages at different levels in the supply chain. Besides, quantitative
data is more likely to remain confidential owing to the very controversial nature of the topic.
Second, no direct comparison can be made between respective countries, as different defini-
tions of drug shortages are used by the medicine agencies for reporting or recording pur-
poses. Therefore, with a view to exploring and gaining a better understanding of the
underlying mechanisms of drug shortages, completing the research gap, as well as assessing
organisational and systematic solutions, a qualitative methodological approach was em-
ployed in this study.
Qualitative Approach to the Drug Shortages Issue
PLOS ONE | DOI:10.1371/journal.pone.0125691 May 5, 2015 2 / 20
Methods
A semi-structured interview was designed to achieve the study objectives. Key professionals
within the medicine supply chain or medicine management, e.g. representatives of relevant
bodies, organisations, or trade associations, were recruited. The interviewees were grouped rel-
ative to their professional roles, and in line with the following criteria:
• national authorities, including medicines agencies, national ministries of health and finance,
reimbursement agencies (policy-makers);
• pharmaceutical companies, including original and generic manufacturers;
• pharmaceutical wholesalers, including wholesale distributors, parallel traders, short- and
full-line wholesalers;
• hospital and community pharmacists.
During a three-month period in the early 2014, a total of 28 stakeholders in France, Belgium
and at the European Union’s (European) level were invited by electronic mail and/or telephone
to participate in the study. Purposive sampling of interviewees entailed inviting a minimum of
two representatives of each stakeholder group in Belgium, France and at European level. Addi-
tionally, the snowball sampling technique was used to recruit the most informative stakehold-
ers. The interviewees who positively replied to the invitation of the research team to participate
in the study were asked to name further professionals within the pharmaceutical sector, who
have extensive knowledge on the topic, extensive understanding of the problem, as well as
those who are or have been professionally involved in developing solutions to the problem.
During the preparatory phase four specialized interview guides were constructed, each of
them relevant to the professional profile of a particular group of stakeholders (S1–S4 Text).
The interview guides were piloted and subsequently refined. They covered the following topics:
understanding the phenomenon of drug shortages, its perceived scope and impact, as well as
possible solutions. Additionally, in order to facilitate the process of interviewing, a table depict-
ing the breakdown of reasons for drug shortages was inserted into each interview guide. It was
based on the report recently published by Birgli [6]. A table was presented to each study partic-
ipant during the interview with a request to express their own opinion on the causes of drug
shortages and to reflect individually on the typology provided therein. Interviews, lasting ca.
60 minutes each, were audio-recorded and then transcribed verbatim. The online software
Transcribe! was used to support the transcription [22]. Transcripts were coded and analysed
using MAXQDA software package, Version 11 [23].
The process of analysing the data involved conducting data reduction and applying constant
comparison techniques. An open coding approach was used to examine the text and to analyse
it by topics. A code was attributed to individual words or sentences, in order to categorize the
data according to their meaning and referenced action. The code would often arise directly
from the data. Codes emerging from early interviews formed a developing coding taxonomy
that was used to analyse subsequent interviews. In some instances, the coding was revised
based on the new data derived from the interviews. Re-coding and a discussion took place in
an effort to ensure that the codes matched the data accurately. Besides the coding, the process
of data reduction entailed writing summaries and memos. Finally, to determine the patterns of
response concerning the understanding of the phenomenon of drug shortages by a particular
stakeholder group, as well as national and European settings, certain segments of the data were
compared within a single case, as well as between various cases.
Several strategies were implemented to ensure scientific rigour in the collection and analysis
of the data. A single researcher conducted all the interviews, although regular consultations
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with other members of the research team were also pursued. Since the interview technique spe-
cifically selected for the purpose facilitated a follow-up of the interviewees, should they raise
any interest in terms of the actual research questions, while at the same time departing from
the set interview guidelines, every interviewer was required to be well versed in the specifics of
the area under study.
In order to be able to follow up the problems raised during the interviews, the interviewing
author carried out a wide literature review prior to the interviews. The interviewing author re-
corded additional information, using a reflective researcher’s log and field notes to aid powers
of recall, thereby ensuring consistency and accuracy of reporting. Memos were used to keep
track of relevant reflections during the analysis of the interviews. These encompassed reflec-
tions on theoretical aspects, data analysis and the researcher’s own impressions. All data were
synthesized under simple codes, while rigorous theoretical thinking led to further refinement
of the explanations, effectively facilitating the attainment of the study objectives.
The limitations typical for qualitative research were duly considered when approaching the
issue of external validity or generalizability of the study results [24]. The constant comparison
technique was used to ensure quality and internal validity of the study, helping to verify coher-
ence and precision between the codes generated during the analysis and the facts, as well as the
problems they referred to. The coding system for all interviews was then revised and optimised.
Additionally, some relevant quotations were provided within the study report in order to en-
hance its overall validity, as well as reflect the actual empirical material with greater accuracy.
Besides, such quotations ensured an acceptable level of validity of the study results, in parallel
with other measures, such as provision of specific examples. Reliability of analysis was also se-
cured by checking transcripts for any transcription mistakes. Finally, data triangulation was
performed to enhance overall credibility of the findings. The phenomenon was studied as un-
derstood by interviewees from four different professional perspectives, as well as both national
and international settings.
The Jagiellonian University (Krakow, Poland), the University of Sheffield (UK), and the
Katholieke Universiteit Leuven (Belgium), granted ethical approval for the study, respectively.
Before the interviews were conducted, the interviewees received detailed information on the
study design. Written informed consent was obtained from all participants who were assured
of data confidentiality and their right to withdraw at any time.
Results
Overall, 21 semi-structured interviews were conducted in person with the key representatives
of various institutions (Table 1). Nine interviewees came from public health authorities. Four
interviewees were from the pharmaceutical companies, four represented the wholesale distrib-
utors and four represented the pharmacies (or their associations, respectively). Data saturation
was achieved with the total number of participants [25]. Qualitative content analysis and data
Table 1. A summary characteristics of the interviewees.
Countries Representatives* of public
health authorities
Representatives of pharmaceutical
companies
Representatives of
wholesalers
Representatives of
pharmacies
Belgium 2 0 1 2
France 6 1 1 1
European Union 1 3 2 1
Total 9 4 4 4
*Public health institutions include medicines agencies, reimbursement agencies, policy-making institutions.
doi:10.1371/journal.pone.0125691.t001
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reduction were used to classify the 135 allocated codes into 14 categories and consequently sev-
eral themes were identified [26]. They comprised: defining drug shortages, their dynamics and
perception, their determinants, the role of the European and the respective national institutions
in coping with the problem.
Defining drug shortages
The interviewees frequently highlighted overall complexity of the drug shortages phenomenon
and the resultant difficulty in agreeing on a common definition. Inconsistency of the nomen-
clature emerging from the analysis was also acknowledged by the interviewees. One interviewee
observed: "How to understand drug shortages is a very complicated issue and subject to some
debate, because some regard a shortage as a situation in which one is unable to get hold of a
medicine within a reasonable time, whereas others define it as medicine which is not really
available on the market at all".
In Belgium, the term “onbeschikbaarheid” (literally translated as unavailability) of medi-
cines is used by national institutions, although other terms, like “tekorten” (shortage) or “stock-
breuk” (stockout) are also being used. Most of the stakeholders in France agreed on using the
terms “rupture d’approvisionnement” and “rupture de stock” (disruptions of supply and stock,
respectively), although their precise meaning was found to be rather confusing, as different def-
initions were offered when asked for the exact meanings of the terms. A disruption of supply
(legislative term) is generally understood as a problem in the distribution chain, whereas a dis-
ruption of stock refers to a problem at the manufacturing level. Also other terms—“rupture
anticipée”, “rupture constatée” (anticipated and actually observed shortages, respectively)—
were used by the French interviewees. An anticipated shortage is reported by a manufacturer,
while an actually observed shortage—by a pharmacist. In English, the term shortage is used
predominantly by the majority of the interviewees. They highlighted the importance of using a
common and well-understood terminology. As an industry representative stated: “We feel it is
the basic block upon which you are going to build. If you do not agree on this, you will face
problems with the interpretation and quantification later on."
A great diversity of opinions regarding the actual level at which drug shortages should be as-
sessed was found to be the second challenge. In Belgium, in line with applicable legislation, a
shortage is deemed to occur when a company at issue is unable to respond to any delivery re-
quests. Under French law, a shortage is construed as the inability of a pharmacy to dispense a
medicine to a patient. However, several interviewees noted that a pharmacist might not be able
to dispense a particular medicine only because his preferred wholesaler happens to be unable
to deliver the product, although it may well be available at a pharmacy nearby. At the European
level, several interviewees agreed on a patient-centred approach, believing a drug shortage is "a
disruption in supply of medicines, affecting the patient’s ability to access the required treat-
ment within the appointed time-frame."
The actual time-frame constitutes the third factor, adding to the overall complexity of the
task of finding a commonly acceptable definition. In Belgium, the law defines a shortage as an
inability to dispense a particular medicine within four days (96 hours), whereas in France a
shortage occurs within 72 hours only. At European level, a “time-frame” has not yet been de-
fined, but one industry representative acknowledged that "a majority of the stakeholders would
be happy to agree on a 48h time-frame."
Whether commercialisation should actually be linked to drug shortages is still a debatable
point—creating a fourth challenge encountered along the way in an effort to define drug short-
ages. For instance, if a product is no longer marketed, should this be regarded as a bona fide
medicine shortage? Some stakeholders at European level, such as the industry representatives,
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completely exclude product discontinuation from drug shortages, although one health authori-
ty representative said that: "A shortage should be duly acknowledged, if a particular medicine is
not actually available on the market at any time after its marketing authorization has been
issued."
The fifth difficulty consists in whether a measure of drug shortage severity should be consid-
ered. Several European associations address the issue of drug shortages at the level of molecules
or active pharmaceutical ingredients (APIs)—a shortage is deemed to occur when a treatment
alternative to a particular active substance is required. A French policy-maker said that a short-
age would not occur, if an alternative treatment could be found within 72 hours, assuming a
non-essential medicine is concerned. The unavailability of a product on the market will duly be
defined as a shortage, although the French medicines agency (Agence Nationale de Sécurité du
Médicament et des Produits de Santé, ANSM) mostly addresses shortages of essential medi-
cines. In Belgium, a drug shortage is assessed by the Federal Agency for Medicines and Health
Products (FAMHP) both in terms of the actual availability of the product itself, as well as in
terms of the specific package sizes that may currently be in demand on the market (i.e. specifi-
cally required by the pharmacies).
Dynamics and perception of drug shortages
According to the majority of interviewees, drug shortages occur daily or weekly in France and
Belgium. However, their durations can vary significantly—from less than a week to an indefi-
nitely longer period of time. One of the wholesalers from France said that 75% of the shortages
lasted up to 2 weeks. Ideally, as another interviewee mentioned, one should have the shortages
split up, depending on the actual causes. Shortages due to manufacturing problems generally
last longer than those due to the supply chain problems. For example, a shortage due to parallel
trade issues would be typically resolved within a week or two, or as soon as a new month be-
gins. The WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies
defines the parallel trade in medicines within the EU as a form of arbitrage in which medicines
are purchased in one Member State and then sold on to other Member States where the income
levels, and hence the pricing, are usually higher [27].
According to our interviewees, when a manufacturing problem occurs, however, sometimes
an entire production chain has to be taken out of commission. If products become contaminat-
ed on the production line, all batches will have to be recalled. Also, when the production site
has quality problems and this comes to the attention of the regulatory institutions, the actual
production run would have to be stopped and resumed only after the manufacturer has duly
complied with all applicable regulatory standards, which may take up to several months.
Research participants, representing French, Belgian and European stakeholders, freely ad-
mitted in the interviews that drug shortages were being increasingly discussed, and the actual
appreciation of the problem has grown within the last decade. Whether this, in fact, should ac-
tually be construed as drug shortages having increased over time was denied by some stake-
holders. The interviewees representing pharmaceutical companies felt that drug shortages
significantly increased with the financial crisis. A Belgian hospital pharmacist claimed that
drug shortages increased significantly in comparison with the situation a decade ago, even
though they are now deemed to have stabilised since last year. One French policy-maker ad-
vised caution, though: “The mediatization of drug shortages is not proportionate to their actual
occurrence (. . .). Also, some players have a vested interest in making the problem of drug
shortages more prominent, i.e. putting more pressure on price negotiations”. Using the term
“mediatization” the interviewee was referring to how often the topic was raised in the media,
taking into consideration that societies are shaped by and dependent on mass-media [28].
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Some stakeholders pointed out that drug shortages had not caused any major public health
problems as yet. Both a policy-maker and an industry representative from France readily ac-
knowledged that drug shortages were not presently deemed a public health hazard. According
to one wholesaler representative, this has caused only some inconvenience to the patients,
at most.
Determinants of drug shortages
The interviewees characterised drug shortages as a multi-layered and multi-faceted issue. They
were asked to determine the actual causes of drug shortages and to reflect on their typology
provided in the Birgli’s report [6]. Out of numerous reasons for the drug shortages referenced
there, the most important ones are ranked further below in a descending order, based on how
frequently they were marked by the interviewees:
1. manufacturing problems,
2. limited manufacturing capacity,
3. parallel distribution,
4. raw material shortages and rationing/quotas,
5. non-compliance with regulatory standards.
According to the interviewees, the determinants of drug shortages are split into the three
main categories (Fig 1).
Manufacturing problems. “There has always been a potential for manufacturing prob-
lems”, said one industry representative. “We have the same quality defects as before. They do
happen and we just have to get them fixed; sometimes this may lead to the closure of a factory”,
explained another one. Reflecting on the typology of reasons for drug shortages, as well as uti-
lizing their own professional experiences, the industry representatives claimed that drug short-
ages being the result of manufacturing problems could be linked to underlying problems with
the raw materials or APIs, inadequately sized production facilities, global sourcing, production
or quality issues, manufacturing capacity issues, or non-compliance with applicable regulatory
Fig 1. Categories and sub-categories of the reported determinants of drug shortages.
doi:10.1371/journal.pone.0125691.g001
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standards. Several interviewees mentioned that concentration and rationalisation of pharma-
ceutical manufacturing actually increased the shortage hazard. A problem encountered within
a single manufacturing site may well lead to major disruption on a global market. Increasingly,
pharmaceutical production has been moved outside of Europe, its chain has changed over
time—evolved and globalised. More countries the world over have become involved in the pro-
cess. A French policy-maker said: “Presently, manufacturers source the products outside their
own continent through multiple traders and, consequently, increase vulnerabilities.” Several
stakeholders acknowledged that production sites of APIs had moved to China or India, which
does not facilitate streamlining of their management, and therefore increases the risks of
drug shortages.
Additionally, globalisation has in fact given the decision-making process an international
dimension. Multinational companies might favour global economic aspects above national pri-
orities and requirements. A hospital pharmacist volunteered an example: “Some pharmaceuti-
cal companies have a higher turn-over than Belgium’s GNP, but then the CEO of such a
company might not even know where Belgium is. Commercial decisions are about business
only and have nothing to do with deontology or ethics. They are just made with the sharehold-
ers in mind first and foremost.”
Also, non-compliance with applicable regulatory standards was cited as leading to short-
ages, following inspections on both the raw materials and the finished products. Marketing au-
thorizations may be withdrawn due to non-conformity to the Good Manufacturing Practice
(GMP) rules, according to one Belgian policy-maker. European associations, representing vari-
ous pharmaceutical market stakeholders, admitted they feared the consequences of the EU Fal-
sified Medicines Directive which introduced tougher rules to control the trade in medicines
[29]. This included an authenticity feature on the outer packaging of medicines, an EU-wide
logo to identify legal online pharmacies, tougher rules on the safeguards and inspection of
manufacturers of active pharmaceutical ingredients, as well as stringent record-keeping re-
quirements for wholesaler distributors. “The Directive’s impact turned out to be rather limited,
though”, assured one industry representative, as the statutorily required export documents
were issued in due time, in association with the key exporting countries.
Distribution and supply problems. Among the distribution and supply problems deter-
mining the drug shortages, the interviewees named such reasons as: just-in-time inventories
and inappropriate levels of stock, parallel distribution, quotas and rationing, and transporta-
tion issues. Just-in-time inventories were acknowledged as an important reason for drug short-
ages. One Belgian hospital pharmacist said: “Due to prevalent economic climate, everyone
started introducing just-in-time inventories. I would translate this into ‘just-too-late’ invento-
ries. No one holds stock anymore, as stock is too expensive.” On the other hand, high levels of
stock can induce drug shortages, according to some stakeholders. A hospital pharmacist of-
fered an example: “This year we induced four stock-outs in Belgium, because we bought all the
products in supply.” As the interviewees reported, when one shortage is barely resolved, anoth-
er can be induced, as the dispensers of medicines tend to build up their stock disproportionate-
ly to the anticipated demand. Similarly, patients build up their medicine stockpile when a
shortage has been announced, explained a French policy-maker, which further induces the
shortfall. Therefore, any official communications regarding medicine shortages need to be han-
dled with care to prevent undue confusion, pointed out the policy-maker.
Parallel distribution turned out to be an extremely controversial issue. As one representative
of the European pharmacies’ environment said: “You cannot deny that parallel distribution is a
factor, but you may not simply point the finger at parallel distribution, either”. In Belgium the
opinions on the subject diverge. A hospital pharmacist, acting also as a policy-maker, said that
parallel distribution was a major reason for drug shortages and noted that the prices of four
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oncological products had recently been authorized to increase up to European average values
in order to prevent parallel exportation. Other policy-makers believe that parallel distribution
does not affect drug shortages, as the pharmacies can still order directly from pharmaceutical
companies. In France, several stakeholders referred to a critical shortage of antiretroviral medi-
cines that occurred due to parallel exports four years earlier on, which received extensive
media coverage and political involvement [30]. This case prompted significantly increased
monitoring of the parallel exports of pharmaceutical products, and consequently reduced the
outflow of essential medicines. Both a French policy-maker and a wholesaler’s representative
claimed that parallel distribution was no longer a public health threat. Pharmaceutical compa-
nies have introduced quotas to limit the amount of products the wholesalers will receive, in an
attempt to control excessive exportation. On the other hand, the wholesalers reported that quo-
tas are difficult to handle, and therefore lead to frequent disruptions in the supply chain to the
community pharmacies.
The issue of quotas is closely related to parallel trade and equally controversial amongst the
stakeholders. Three different types of quotas were discussed during the interviews and identi-
fied as appearing at the following levels: (i) pharmaceutical companies, (ii) wholesaler distribu-
tors, (iii) pharmacies. Considering the first level of quotas, the number of units which a
pharmaceutical company can sell on a national market can be restricted in two ways: either by
national institutions through the restrictions on public expenses, or by multinational pharma-
ceutical companies allocating their stock to individual countries or regions, considering limited
manufacturing capacity, or the actually pursued economic strategies. In this case, quotas can
be based on anticipated demand, historical data, financial analyses or country-specific
requirements.
The second type of quotas are those imposed by the pharmaceutical companies on particu-
lar wholesalers. The number of units a wholesaler distributor might be allocated by a manufac-
turer causes numerous conflicts. According to one pharmacy representative, these quotas are
the primary reason for drug shortages in the community pharmacies. Usually they occur at the
end of a month and last around 10 days. A French community pharmacist added: “Quotas are
difficult to explain to patients (. . .). You have to explain that within a public health domain
there are some strict economic constraints due to which the actual availability of a specific
medication in demand may not be assured.” Additionally, quotas trigger conflicts between pre-
scribers and pharmacists: “A pharmacist says he is unable to get hold of a specific medicine,
even though the prescriber has received confirmation directly from the manufacturer on the
product’s availability.”
Several interviewees doubted whether the quotas were well calibrated. Wholesalers urge for
transparency which may then leave plenty of room for efficient planning ahead. A wholesaler
representative explained quotas might well be applied and handled through different systems:
“Some manufacturers will deliver more units, if a wholesaler is out of stock, but others will refuse,
or deliver directly to the pharmacist. The biggest problem occurs when the manufacturers impose
the ‘black-box’ quotas (. . .). In such cases they will not communicate with a wholesaler unless
they have reached the total amount of products allocated by the manufacturers.”How quotas are
actually defined is classified information, however, the stakeholders stated they were based on
IMS Health data and applied mostly to highly-priced products. With regard to the third type of
quotas at pharmacy level, there is a knock-on effect of the wholesaler quotas on pharmacies, as
wholesalers also tend to limit the amount of products that can be ordered by a single pharmacist.
Economic aspects. The price component was revealed to be an important determinant of
drug shortages. An industry representative indicated that registration and maintenance costs,
related to e.g. pharmacovigilance and post-approval activities, have multiplied, especially after
adoption of the “Pharmaceutical package”, launched in 2008 by the European Commission,
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containing legislative proposals aimed to form a new vision for the pharmaceutical sector
(among others, it contained the proposals aiming to improve market access and accelerate re-
search, tackle the problems with counterfeiting and illegal distribution of pharmaceuticals, fa-
cilitate patients’ access to pertinent information on the prescription-only medicines, and
strengthen the pharmacovigilance systems throughout Europe).
Operating costs are much higher than ten years previously, and the industry has grown
more reluctant to market medicines at any cost. Pharmaceutical industries are also undergoing
restructuring as margins have dropped, reimbursement of medicines has been cut, and research
and development pipelines are apparently running dry. Consequently, when a company’s prof-
it is too small, further investments will inevitably be shelved, and this will eventually pave the
way for future manufacturing problems, acknowledged a pharmaceutical company representa-
tive. He also said: “Manufacturing problems tend to increase when operations are not sustain-
able in general; therefore they are more a symptom than a cause.”
Furthermore, current pricing strategies have resulted in product discontinuation, especially
with regard to the long-standing and the lower-priced medicines. According to a French poli-
cy-maker, some older generation antibiotics were discontinued due to low profitability. After
negotiations their prices were re-evaluated, since no alternatives were available on the market,
while the products were deemed essential. Another French government representative pointed
out that measures to resolve shortages might well prove very expensive. Hence all the issues re-
lated to medicine availability should be taken into consideration during any price negotiations.
Purchasing strategies, including reference pricing and tendering have significantly impacted
drug shortages, according to several European stakeholders. According to the definition of the
WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, interna-
tional or external reference pricing is the practice of using the price of a medicine in one or sev-
eral countries in order to derive a benchmark or reference price for the purposes of setting or
negotiating the price of the product in a particular country [27]. Tendering is a formal and
competitive procurement procedure through which offers are requested, received and evaluat-
ed for the procurement of pharmaceuticals, and as a consequence of which an award is made
to the tenderer (bidder) whose offer is the most advantageous [27].
“International reference pricing has affected access to medicines in the low-priced markets,
because manufacturers will try to get their products out of those markets, if the product is refer-
enced in a basket of the high-priced Member States”, said an industry representative. According
to another one, tendering has two limiting aspects, i.e. adverse effects of selecting a sole supplier,
and having a tender awarded to a supplier exclusively on pricing considerations, whereas the
product availability aspect also needs to be taken on board. There is always a risk that an exclu-
sive manufacturer might not be able to cope with an unexpected surge in demand for the prod-
ucts. Besides, other manufacturers will cease production and will therefore be unable to
compensate for the shortage, should the exclusive manufacturer who won the tender, run into
serious production problems. A French policy-maker concurred: “Often the cheapest deal is
made rather than the best one. Eventually, if a shortage occurs, you end up paying, anyway.”
Role of the European and national institutions
The role of the European Union was referred to by the interviewed stakeholders as related pri-
marily to overall coordination. According to one wholesaler representative, European institu-
tions should monitor manufacturing problems, ensure transparency, and give an early warning
with regard to any centrally registered drug shortages. However, this interviewee did not sug-
gest any specific institution. Representatives of the European associations put forward the need
for a steering committee at the European level to take the lead.
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According to a representative of a medicine agency, working groups at the European Medi-
cines Agency (EMA) have been set up to hammer out a European strategy addressing immi-
nent and presently occurring drug shortages. Currently, the Member States are individually
setting up rules and regulations to protect their own markets and patients, thereby creating ad-
ditional imbalances, declared a French policy-maker. For some essential products, an EU ap-
proach should be considered, to assure availability across the entire Union. Currently, when a
shortage occurs, Member States are in direct competition with each other instead of working
hand in hand to resolve the issue effectively, he added.
A community pharmacy representative was surprised by the lack of interest concerning
drug shortage issues at the European level, which (as he claimed) was the result of holding back
from various conflicts and tensions. In his view the European Commission would not like to
intervene in the pricing and reimbursement policies, even though it believed it was actually the
principal reason for the shortages. Consequently, medicines are moved from the markets
where the prices are lower to the ones where they can fetch higher prices. “Parallel distribution
is a pure creation of the European internal market. (. . .) So I suppose you could say, to the ex-
tent that parallel distribution is an issue, that it is an European issue. ‘European laws’ allow you
to set quotas for public health reasons, but nobody knows what the correct position is, or
where to actually draw the line”, continued the interviewee.
A wholesaler representative admitted that there is no specific guidance on how the Member
States should deal with Article 81, Directive 2001/83/EC, and the principles of free movement of
goods, and the competition law. It is difficult for the Commission to officially communicate on
the topic. However, within the very fold of the Commission itself quite divergent opinions are
expressed about the role of parallel trade in the pharmaceutical industry, said an interviewee.
One industry representative added: “You might find DG SANCO and DG Enterprise torn
on how to address the issue. Member States will not want them to set forth any guidelines on
anything because it is their sovereign right.” The DG SANCO and DG Enterprise are abbreviat-
ed names of two departments of the European Commission. The first one deals with public
health issues and as of 2015 it has been named DG Sante (the Directorate-General for Health
and Food Safety). The other one deals with industrial policies and as of 2015 it has been named
DG Growth (the Directorate-General for Internal Market, Industry, Entrepreneurship and
Small and Medium-Sized Enterprises).
On a national level, Member States have arranged for early warning systems. One Belgian
pharmacist believed that respective national agencies should primarily be responsible for col-
lecting information on any drug shortages (including information on alternative treatments) in
real time, and then make it freely available to all healthcare providers. Second, the government
should deal with quality and production problems. Another Belgian pharmacist argued: “The
government becomes aware of the shortages far too late, because companies do not wish to
communicate with anyone about the shortages. Companies do not want to be registered on the
shortage list to prevent their competitors from submitting a request for the derogation of im-
ports.” In France, a wholesaler believed the government should also raise awareness among the
stakeholders to stimulate collaboration and introduce specific measures against drug shortages.
European representatives of stakeholders’ associations pointed out the influence of national
payers and respective ministries of health on pricing and reimbursement issues.
Discussion
This study highlights several important issues underlying drug shortages in the European
Union, thus aiding understanding of a rather complex nature of this problem, its origins and
potential resolution methods. Drug shortages are a complex phenomenon of global impact [5].
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Within Europe, drug shortages have been investigated so far only within a limited scope [1,
31–33].
As our interviewees reported, the differences in the terminology applied to describe the
drug shortages are encountered in Belgium and France. Admittedly, a diversity of definitions
are also internationally acknowledged. The International Society for Pharmaceutical Engineer-
ing (ISPE) defines them as “a situation in which the total supply of an approved (by an appro-
priate Health Authority) medicine is inadequate to meet the current projections or projected
demand at the user level” [34].
The Food and Drug Administration (FDA) defines a drug shortage more narrowly, as “a sit-
uation in which the total supply of all clinically interchangeable versions of an FDA-regulated
medicine is inadequate to meet the current or projected demand at the user level”. Additional-
ly, the FDA adds a public health factor to it, focusing on the shortages of medically necessary
products that have a significant effect on the population’s health [35]. The definition used by
the FDA is based on section 506C(h)(2) of the Food, Drug and Cosmetic Act, according to
which a drug shortage is “a period of time when the demand or projected demand for the drug
within the United States exceeds the supply of the drug” [36]. On the other hand, the American
Society of Health-System Pharmacists (ASHP) defines a drug shortage as “a supply issue that
affects how the pharmacy prepares or dispenses a medicine product or influences patient care
when prescribers must use an alternative agent”. In those cases, a broader definition is used in
which a drug shortage has the potential to compromise patient care [37].
Similar to the FDA, the European Federation of Pharmaceutical Industries and Associations
(EFPIA) defines medicine shortages as “a crisis situation caused by the inability of any Market
Authorization Holder (MAH) to supply a medicine with a specific API to a market over an ex-
tended period of time resulting in the unavailability of this medication for patients” [38]. Final-
ly, the EMA takes into account only drug shortages which could lead to public health crises
that arise due to disruptions within the manufacturing process, caused by manufacturing or
GMP compliance problems [39].
The difficulty in defining and categorizing drug shortages may to some extent be related to
the lack of transparent quantitative data on drug shortages [6,30]. As the material from the in-
terviews with stakeholders from various specializations demonstrates, they still struggle to
agree on a common terminology. The term “shortage” does not seem broad enough to describe
the different aspects of a shortage and creates confusion amongst the stakeholders. Drug short-
ages may be perceived from different angles with each of the stakeholders adhering to his own
view. A shortage at the manufacturer’s level is not due to the same causes and consequences as
a shortage at the pharmacist’s level. Nonetheless, the perspective of a manufacturer and a phar-
macist is adopted, respectively, to describe a shortage in line with applicable constraints of Bel-
gian and French legislation. It should also be clearly said at this juncture, however, that in both
Belgian and French legislation instead of making consistent use of the term “shortage”, the
terms “unavailability of a medicine” and “disruption of supply” are used interchangeably.
As may readily be seen from our interviews, defining and categorizing drug shortages is also
difficult, due to the fact that one has to decide on the actual time-frame, whether to include a
measure of severity, and whether to include any discontinued products. Consequently, making
use of a single word may not be entirely appropriate, as it would most obviously fail to embrace
the different aspects of drug shortages. Depending on the cause and the severity of a shortage,
different terminology should be applied instead. As the issue of medicine shortages is discussed
in more depth, researchers, analysts and readers of thematic reports should become fully aware
of the inconsistency within the currently applied nomenclature, with the need for a compre-
hensive glossary of pertinent terms becoming paramount.
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Although the stakeholders interviewed for the purpose of this study do agree that drug
shortages occur regularly, it is difficult to assess the actual severity of the situation. In Europe,
the exact figures regarding drug shortages are not available, despite an increasing number of re-
ports and studies on the issue [6,8,31,32,38,40–43]. The EMA has recently compiled a shortage
catalogue which comprises information on drug shortages that either affect, or are likely to af-
fect more than one of the European Member States [44]. However, the shortage catalogue fails
to provide a comprehensive listing of drug shortages, as most of them are dealt with at a
national level.
In the winter of 2012–2013, the European Association of Hospital Pharmacists (EAHP) car-
ried out a survey in hospital pharmacies [43]. The study revealed that 99% of hospital pharma-
cies experienced drug shortages in the previous year, with 63% of the participants reporting
weekly, or sometimes daily, shortages. Additionally, 77% of hospital pharmacies reported that
drug shortages became worse in the previous year. Generic and original medicines seemed
equally affected, but differed when the respondent’s country was taken into account. The areas
of medicine that were most affected included oncology (70.6%) and cardiovascular disorders
(43.8%).
As our interviewees admitted, both hospital and community pharmacies were also affected
by drug shortages. This seems to corroborate the findings published elsewhere. In late 2012,
the Pharmaceutical Group of the European Union (PGEU) conducted a survey among its
members [7,45]. All respondents reported drug shortages, although their severity varied. Ac-
cording to the survey, the situation grew worse in the past 12 months, and a broad range of
medicines was affected, including generic and branded medicines. As the results yielded by the
present study have partly corroborated, some pharmacy associations regularly produce a list of
medicines in short supply (e.g. the Irish Pharmacy Union and the Dutch Royal Pharmacy Soci-
ety) [45]. Likewise, in other countries the regulators have set up specific websites in order to
keep the stakeholders regularly advised about any unavailability of medicines, whereupon per-
tinent information is mostly provided by the manufacturers on a voluntary basis (e.g. Belgium,
but also Italy and Lithuania) [45].
As far as Belgium is concerned, 143 products were listed by the FAMHP as temporarily un-
available (a counting unit including product name, formulation and dose) in March 2014 [46].
Additionally, 11 medicines were separately reported, as their unavailability could lead to a pub-
lic health hazard or pose a tangible threat to patients who should receive the treatment. Notice-
ably, the two major therapy areas in which shortages occurred predominantly in Belgium, were
the disorders of the nervous system and of the cardiovascular system. The majority of the re-
ported drug shortages pertained to the generic products.
With regard to France, the ANSM reported 34 drug shortages, 13 product discontinuations,
13 products with an imminent shortage, and 20 products with restored availability (a counting
unit including the product name and its formulation) in March 2014 [47]. The therapy area in
which most of the drug shortages occurred concerned treatments targeting diseases of the ner-
vous system. This was followed by the shortages of anti-infective, anti-neoplastic and
immunomodulatory medicines.
It seems that drug shortage issues are more prominent in the USA than in the EU, as an in-
creased number of shortages has been reported there within the past decades, intensifying even
more in recent years [48,49]. Within the period spanning 2006–2011, the ASHP reported a
three-fold increase in drug shortages [49–51]. It is also shown in Fig 2, where the adjacent col-
umns represent the number of new shortages within each year. On 8 January 2014, there were
239 drug shortages published on the ASHP website [52]. The FDA registered by generic name
or active ingredient 73 medicines currently in shortage and 33 with the status of resolved
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shortages (as of 15 February 2015) [53]. The drug shortage problem mostly affects older gener-
ic injectable medicines in the therapeutic domains of oncology and anti-infective treatments
[54].
Whenever the actual determinants of drug shortages were concerned, no single aspect had
been decisively indicated by our interviewees as dominant. However, the economic aspects
seemed to have claimed a leading role, effectively determining commercial decisions of the
pharmaceutical market stakeholders. Manufacturing problems and product supply issues were
suggested in other published sources as the most important reasons for shortages [31,54]. Simi-
lar to the situation in the EU, the multi-causal character of drug shortages was also reported in
the USA [51].
Rationalisation and consolidation of the industry has increased vulnerabilities in the
manufacturing and the supply chain. Nowadays, there are fewer manufacturing sites and APIs
are sourced outside Europe. Furthermore, manufacturers use the same production line for mul-
tiple products, which can limit production capacity [55]. Consequently, a specific problem en-
countered within one production site may well lead to a global crisis [51,55]. In general,
manufacturing problems also tend to increase when operations are not sustainable. Besides,
economic aspects are inter-related with distribution and supply problems. In order to reduce
the cost of inventories and optimise cash flows, the stakeholders tend to opt for the just-in-
time inventory management, which increases overall susceptibility to shortages when a change
in demand or supply should unexpectedly occur.
Parallel distribution is also based on economic decisions, as the products are exported to the
higher-priced countries and subsequently sold there for extra profit. Pharmaceutical compa-
nies are the main exporters of pharmaceutical products in France [30]. However, their anxiety
with regard to parallel export that might potentially be pursued by the wholesale distributors,
or their belief that this might already be going on, inevitably lead the pharmaceutical compa-
nies to introduce quotas as an effective counter-measure. Quotas are also implemented by
(multinational) pharmaceutical companies that allocate stock to individual countries in view of
a limited manufacturing capacity, or specifically tailored economic strategies. Whether it is ac-
tually the quotas or parallel trade that leads directly to drug shortages, is a hotly debated issue
Fig 2. Drug shortages in the USA spanning January 2001—December 2014 [58].
doi:10.1371/journal.pone.0125691.g002
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amongst the stakeholders, according to our study participants. The consequences may be quite
significant, however, and affect mostly the medicines dispensed by the community pharmacies.
Drug shortages may also be impacted directly by some economic aspects, according to our
study, as well as to other published sources. For example, a lack of market attractiveness and
low profitability may prompt the discontinuation of some long-standing, or lower-priced prod-
ucts, e.g. antibiotics and oncologic medicines [1,5,10,48]. Pricing strategies, such as reference
pricing and tendering, may actually influence a manufacturer’s decision to keep a product on
the market. A company might decide to pull out of production, if a tender is lost, or remove its
product from the market, should it lead to a loss of profits in a higher-priced country [6]. Final-
ly, regulatory compliance requirements related to pharmacovigilance and post-authorisation
activities may also prove costly [6,39].
Manufacturing problems and quality defects seem to influence the injectables more often
than other formulations, due to the complexity of their production [31,56]. The economic de-
terminants seem to exert a particularly strong influence on the shortages of generic injectables,
at least in the USA [31,56]. In one of the recently published studies the generics were not re-
ported as outnumbering the branded medicines within the statistics on drug shortages in Bel-
gium, the Netherlands, the United Kingdom, Germany, Italy, Spain and France [31]. However,
according to its authors, this could actually be attributable to the inherent limitations of the re-
porting systems in those countries. When essential medicines and oncology drugs were studied
(sub-analysis of the same study results), overall share of generic injectables in the shortages in-
creased appreciably. Similarly, in the USA, the majority of pharmaceuticals in short supply had
oncology indications [31,51,54,57].
The present study corroborates the global character of drug shortages, as well as the impor-
tance of international links and relations in understanding and coping with this problem. In
spite of that, the participants’ statements indicate that there seems to be a profound lack of in-
terest in this issue at the European level.
On the one hand, respective national institutions keep on developing and implementing di-
verse regulations regarding prices and general availability of medicines. In fact, national poli-
cies do play a pivotal role, as they can effectively influence commercial decisions and,
consequently, overall sustainability of the market. As pricing negotiations may well persuade a
manufacturer to keep a specific product on the market, the institutions in charge of regulating
the prices of medicines should closely collaborate with the ones regulating the actual availabili-
ty of the medicines. National authorities need to put some pressure on the stakeholders in
order to find a middle ground between their goals and objectives and the actual implementa-
tion of specific measures to ensure a continuous supply of medicines, with a view to effectively
protecting public health. In turn, policy-makers are challenged to reduce health care expendi-
ture in the services without compromising the quality and availability of the products. Eventu-
ally, the responsibility for access to and the supply of medicines rests with the respective
national authorities.
On the other hand, as our interviews seem to imply, the rules and regulations which are in-
dividually set up by the national authorities, primarily in order to protect their market and pa-
tients, create imbalances at the European level. The effect of the interaction between Member
States on drug shortages therefore needs to be monitored at the European level. The European
institutions need to coordinate the common European approach to assure the availability of
medicines, as well as to deal effectively with the manufacturing problems impacting the EU as
a whole. Also the effect of European directives and regulations should be monitored by the EU
institutions. Non-compliance with applicable regulatory standards may lead to drug shortages,
e.g. due to non-conformity with the GMP rules, or (at least potentially) as a consequence of
duly implementing the provisions of the EU Falsified Medicines Directive. Based on our
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interviews, the Member States should also be specifically guided on how to deal with applicable
European directives and regulations.
The present study has several limitations, partly inherent to the adopted methodology and a
rather complex nature of the problem. They pertain both to the country selection and the pop-
ulation sample of the interviewed stakeholders. Although the issue of drug shortages is of para-
mount importance across several countries, only two of them were assessed. Some important
stakeholder groups were not included due to the actual study design and specific time-line con-
straints. For instance, the representatives of patients and prescribers might well have revealed
other important aspects of drug shortages. However, the in-person, semi-structured interviews
with 21 professionals active in relevant institutions and organisations facilitated an in-depth
and broad appraisal of the problem under study. The high response rate gave us the opportuni-
ty to assess the different perspectives and complexities which characterise all drug shortages.
To the best of our knowledge, this is the first qualitative study to investigate the characteris-
tics, the determinants, and the problem drivers of drug shortages, focusing on this particular
group of countries, while also adopting the European Union’s perspective. Additional studies
should obviously be pursued to better quantify and further identify the underlying causes of
drug shortages in the entire EU, in order to develop long-term prevention strategies and
strengthen any specifically focused mitigation responses.
Conclusions
Drug shortages have increasingly been reported in Belgium and France. They occur daily or
weekly, and their durations can vary significantly—from less than a week to an indefinitely lon-
ger period of time. Appreciation of this issue has increased within the last decade. However,
whether this should actually be construed as the drug shortages having, in fact, increased over
time was denied by some stakeholders.
Defining drug shortages was found to be exceedingly complicated by a great diversity of
opinions on the level at which all drug shortages should be assessed, the appropriate time-
frame applied, the issue of linking commercialisation to shortages, and finally—by the severity
of the problem itself. The commonly agreed terminology should effectively be developed to fa-
cilitate popular appreciation of its underlying causes, intensity and complex character.
Three groups of determinants of drug shortages were identified throughout the present
study: manufacturing problems, distribution and supply problems, and problems related to
some economic aspects. Manufacturing problems stem from concentration and rationalisation
of pharmaceutical manufacturing, as well as globalisation. Keeping communication lines with
the stakeholders open at all times was found to be crucial in order to minimise the distribution
and supply problems. Both parallel distribution and quotas turned out to be extremely contro-
versial issues. Economic aspects seem to play a pivotal role in drug shortages, effectively im-
pacting commercial decisions made by all of the interviewed stakeholders. Rationalisation and
consolidation of the industry has increased vulnerabilities in the production and supply chain.
Furthermore, pricing and reimbursement strategies seem to have a considerable impact on
drug shortages.
EU institutions need to coordinate legal and organisational strategies to address the issue of
drug shortages between all Member States. Presently, they seem to express rather low, if any,
interest in having this problem effectively resolved. Far more focused and dedicated collabora-
tion among the Member States might well prove instrumental in coping with drug shortages
throughout the European Union more effectively.
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